联环药业(600513) - 2017 Q1 - 季度财报
JLPCJLPC(SH:600513)2017-04-19 16:00

Financial Performance - Operating revenue fell by 15.76% to CNY 132,299,804.51 year-on-year[5] - Net profit attributable to shareholders increased by 4.39% to CNY 13,035,272.02 compared to the same period last year[5] - Total operating revenue for Q1 2017 was ¥132,299,804.51, a decrease of 15.74% compared to ¥157,047,216.48 in the same period last year[21] - Net profit for Q1 2017 was ¥13,009,236.54, up 4.42% from ¥12,457,712.34 year-over-year[23] - Operating profit for Q1 2017 was ¥15,558,697.64, slightly up from ¥14,812,248.79, an increase of 5.02%[23] Cash Flow - Net cash flow from operating activities decreased by 44.30% to CNY -13,890,077.70[5] - Total cash inflow from operating activities for Q1 2017 was CNY 138,855,642.80, an increase of 5.4% compared to CNY 131,685,838.25 in the same period last year[28] - Net cash outflow from operating activities was CNY -13,890,077.70, worsening from CNY -9,625,797.30 in Q1 2016[28] - Cash inflow from financing activities was CNY 40,500,000.00, up from CNY 31,500,000.00 in the previous year, representing a 28.6% increase[29] - Net cash outflow from financing activities was CNY -4,036,110.62, compared to CNY -1,225,846.49 in Q1 2016[29] - The company experienced a net cash decrease of CNY 25,936,507.86 during the quarter, compared to a decrease of CNY 12,783,799.57 in the same period last year[29] Assets and Liabilities - Total assets decreased by 3.01% to CNY 1,034,169,149.34 compared to the end of the previous year[5] - Total current assets decreased from CNY 794,079,575.88 at the beginning of the year to CNY 765,420,847.60, reflecting a decline of approximately 3.3%[12] - Total liabilities decreased from CNY 239,031,207.78 to CNY 193,907,168.60, a reduction of approximately 18.9%[14] - The total assets decreased from CNY 1,066,283,951.98 to CNY 1,034,169,149.34, indicating a decline of about 3%[15] - Total liabilities decreased to ¥134,381,989.01 from ¥136,287,686.28, a decline of 1.40%[19] Equity and Retained Earnings - The company's retained earnings increased to CNY 259,803,030.97 from CNY 246,767,758.95, reflecting a growth of approximately 5.3%[15] - The total equity attributable to shareholders rose from CNY 826,704,917.13 to CNY 839,740,189.15, an increase of about 1.3%[15] - The company's equity increased to ¥797,510,385.82 from ¥787,159,383.73, marking a growth of 1.69%[19] Inventory and Accounts - The company's inventory increased to CNY 74,326,849.40 from CNY 64,967,181.42, marking a rise of about 14.5%[13] - The company's accounts receivable decreased from CNY 162,202,860.11 to CNY 154,380,336.14, a reduction of about 4.8%[12] - The company reported a significant reduction in accounts payable by 48.24% to CNY 26,527,742.71[9] Other Financial Metrics - The weighted average return on equity decreased by 0.04 percentage points to 1.56%[5] - The company reported a significant decrease in sales expenses, which fell to ¥43,197,881.34 from ¥45,630,922.85, a reduction of 5.35%[21] - Investment income showed a loss of ¥17,108.00 compared to a gain of ¥793,462.93 in the previous year, indicating a significant decline[21] - Cash and cash equivalents decreased from CNY 431,072,058.75 to CNY 405,135,550.89, a decline of approximately 6%[12] - Total cash outflow from investing activities was CNY 7,996,919.93, compared to CNY 21,868,895.82 in the same period last year, indicating a reduction of 63.4%[29]